About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker VXRT · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Oct 9, 2026A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-…
NCT06672055 · SARS-CoV2, COVID-19
VXA-CoV2-3.1, COMIRNATY®
VXRT
Vaxart
Phase 2Active, not recruiting5,485May 2027Registry ↗
Jul 27, 2026A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18…
NCT06944717 · Norovirus Infections
VXA-G1.1-NN, VXA-G2.4-NS
VXRT
Vaxart
Phase 1Completed60Apr 14, 2026Registry ↗
Apr 15, 2026A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Female…
NCT07254728 · Norovirus Infections
VXA-G1.1-NN, VXA-G2.4-NS
VXRT
Vaxart
Phase 1Completed76Dec 13, 2024Registry ↗
Nov 5, 2025Norovirus Challenge Study
NCT05212168 · Norovirus Infections
VXA-G1.1-NN, Placebo Tablets
VXRT
Vaxart
Phase 1/2Completed165Apr 13, 2023Registry ↗
Apr 15, 2025A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy V…
NCT05626803 · Norovirus Infections
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to th…
VXRT
Vaxart
Phase 2Completed135Oct 16, 2023Registry ↗
Apr 13, 2025A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine
NCT05067933 · COVID-19
VXA-CoV2-1.1-S, Placebo Tablets
VXRT
Vaxart
Phase 2Terminated66Jun 10, 2022Registry ↗
Jun 21, 2024A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen…
NCT05213728 · Norovirus Infections
VXA-G1.1-NN
VXRT
Vaxart
Phase 1Completed8Feb 1, 2022Registry ↗
Jun 21, 2024Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-…
NCT04563702 · Covid19
VXA-CoV2-1
VXRT
Vaxart
Phase 1Completed35Oct 10, 2021Registry ↗
May 22, 2024Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines
NCT04875676 · Norovirus Infections
VXA-G1.1-NN
VXRT
Vaxart
Phase 1/2Completed30Oct 30, 2021Registry ↗
Feb 13, 2023Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine
NCT04854746 · Norovirus Infections
VXA-GI.1.NN, Placebo Tablet
VXRT
Vaxart
Phase 1Completed66Jan 4, 2022Registry ↗
Oct 6, 2022A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasona…
NCT02918006 · Influenza
VXA-A1.1, Fluzone®
VXRT
Vaxart
Phase 2Completed179Aug 8, 2017Registry ↗
Sep 21, 2022Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines
NCT03897309 · Norovirus Infection
VXA-G1.1-NN, VXA-G2.4-NS
VXRT
Vaxart
Phase 1Completed86Jan 15, 2021Registry ↗
Aug 16, 2018Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-R…
NCT02830932 · Respiratory Syncytial Virus (RSV)
VXA-RSV-f Tablets (high dose), VXA Placebo Tablets
VXRT
Vaxart
Phase 1Completed66Sep 16, 2016Registry ↗
Jul 20, 2018A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Ap…
NCT02724254 · Condyloma
AP611074 5% gel, AP611074 matching placebo
VXRT
Vaxart
Phase 2Completed218May 2018Registry ↗
May 31, 2018Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine
NCT02868073 · Norovirus Gastroenteritis
VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA Placebo Ta…
VXRT
Vaxart
Phase 1Completed66Oct 5, 2016Registry ↗
May 31, 2018Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration…
NCT02547792 · Seasonal Influenza B
VXA-BYW.10 (Low Dose) Oral Vaccine, VXA-BYW.10 (High Dose)…
VXRT
Vaxart
Phase 1Completed54Nov 21, 2016Registry ↗
May 30, 2018Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers
NCT03125473 · Norovirus Gastroenteritis
VXA-G1.1-NN Oral Vaccine
VXRT
Vaxart
Phase 1Completed66Jul 1, 2017Registry ↗
May 30, 2018Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults
NCT03121339 · Seasonal Influenza Preventative Vaccine Pharmacodynamics
VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vacc…
VXRT
Vaxart
Phase 1Completed8May 5, 2017Registry ↗
May 7, 2018A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhi…
NCT03024177 · Rhinovirus, Upper Respiratory Tract Infection
Vapendavir, Placebo Oral Tablet
VXRT
Vaxart
Phase 2Withdrawn0Apr 2017Registry ↗
May 12, 2017Safety Study of an Oral Vaccine to Prevent Seasonal Influenza
NCT01688297 · Influenza
VXA-A1.1 Oral Vaccine, VXA Placebo Tablet
VXRT
Vaxart
Phase 1Completed61May 2014Registry ↗

20 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:48 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances